

1016 Supplementary Information

1017

1018 **Defining the extracellular matrix in non-cartilage soft tissues in osteoarthritis – a**

1019 **systematic review**

1020 Jolet Y. Mimpfen<sup>1\*#</sup>, Iwan G. A. Raza<sup>2#</sup>, Sarah J. B. Snelling<sup>1</sup>

1021 <sup>1</sup> *Botnar Research Centre, Nuffield Department of Orthopaedics Rheumatology and Musculoskeletal*

1022 *Sciences, University of Oxford, Oxford, UK*

1023 <sup>2</sup> *Medical Sciences Division, University of Oxford, UK*

1024 # Jolet Y. Mimpfen and Iwan Raza contributed equally to this work

1025

**Supplementary Table 1.** Study characteristics of included human studies.

**Abbreviations:** ACL = anterior cruciate ligament, IQR = interquartile range, KCS = Knee Society Clinical Grading System, KL-grade = Kellgren-Lawrence grade, Med = median, NR = not reported, OA = osteoarthritis, OARSI = Osteoarthritis Research Society International, OCS = Outerbridge Classification System, PCL = posterior cruciate ligament, TKR = total knee replacement.

\* = note on the control group of Herbert (1973): although 15 participants were in the control group in total, results in this review are based on the included adults only (11 participants).

# = note on the control group of Karube (1981): although non-adult participants were included in the study, the results in this review are based exclusively on the age groups with adults only.

First author (year)	Country	Joint	Tissue (details)	Stage of disease / OA severity	Control population	No. of participants	Female (%)	Age (mean±SD (range))	BMI (mean)	Ref
Abdul Sahib (2017)	Iraq	Knee	Ligament (ACL & PCL)	NR	No	OA: 50	70	NR	NR	[33]
Abraham (2014)	USA	Knee	Meniscus (entheses)	Advanced	Healthy tissue donors	OA: 7 Control: 8	NR NR	NR 55 (41-61)	NR NR	[47]
Akisue (2002)	Japan	Knee	Ligament (PCL)	Ahlbäck grades 2-5	Cadavers w/o knee OA	OA: 24 Control: 4	38 50	64.2 (40-84) 87 (78-98)	NR NR	[34]
Allain (2001)	France	Knee	Ligament (ACL & PCL)	TKR	No	OA: 45	67	76 (68-84)	NR	[35]
Atik (2016)	Turkey	Knee	Meniscus (medial)	Medial arthroplasty	No	OA: 12	100	64 (59-71)	NR	[48]
Battistelli (2019)	Italy	Knee	Meniscus	KL grade 3-4	Multi-organ donors w/o history of joint disorders	OA: 3 Controls: 3	33 33	Med 72 (IQR 72-73.5) Med 66 (IQR 63-69)	NR NR	[49]
Belluzzi (2020)	Italy	Knee	Fat pad (infrapatellar)	End-stage	ACL reconstruction, med 8 months post-injury	OA: 25 Control: 28	72 25	Med 68 (IQR 62-75) Med 31 (22-42)	Med: 29.5 Med: 23.0	[31]
Cameron (1973)	Canada	Hip	Capsule	End-stage	Not reported	OA: 25 Control: 15	NR NR	NR NR	NR NR	[25]
Campbell (2015)	Canada	Knee	Capsule	Mean KL grade >3	No	OA: 21	57	Mean >65	NR	[26]

Chang (2005)	Japan	NR	Synovium	Arthroplasty	No	OA: 5	NR	NR	NR	[121]
Cheng (1996)	Belgium	Spine	Intervertebral disc	KL grade 1-4	Cadavers w/o spinal OA	OA: 51 Control: 9	50	67.3 (23-87)	NR	[32]
Christensen (2019)	Denmark	Hip	Synovium	Advanced	No	OA: 6	3	Med 66.5 (IQR 62–69)	Med 30.8	[108]
Cillero-Pastor (2015)	Netherlands	Knee	Synovium	TKR	Adult tissue donors	OA: 3 Control: 3	NR NR	69-82 60-78	NR NR	[92]
Cutolo (1992)	Italy	Knee	Synovium	End-stage	Knee trauma	OA: 4 Control: 4	NR NR	NR NR	NR NR	[93]
Dessombz (2013)	France	Knee	Meniscus (medial)	KL mean grade 4	No	OA: 6	83	74 (SD 9)	28	[50]
DiCesare (1999)	USA	Knee	Synovium	Knee replacement	No	OA: 3	NR	NR	NR	[94]
DiFrancesco (1995)	USA	Hip	Capsule	Advanced	No	OA: 109	57	67.1 (39-92)	NR	[27]
Dijkgraaf (1997)	Netherlands	TMJ	Synovium	Early to advanced	No	OA: 31	81	30.1	NR	[119]
Doerschuk (1999)	USA	Thumb	Ligament (palmar beak)	Mankin grades 3-14	No	OA: 18	72	NR	NR	[45]
Ea (2013)	France	Knee	Synovium	KL grades 0-3	No	Total: 31	NR	NR	NR	[95]
Ene (2015)	Romania	Knee	Synovium	Early and late stage	No	OA: 43	77	49-76	NR	[96]
Exposito Molinero (2016)	Spain	NR	Tendon (Achilles)	NR	No	OA: 24	46	50.7	NR	[131]
Fan (2012)	China	Knee	Synovium	NR	No	OA: 6	50	Med 60 (range 48-77)	NR	[97]
Fink (2007)	Germany	Knee	Skeletal muscle (vastus medialis)	KL grade 4	No	OA: 78	79	68.5 (51-83)	<20: 3 20-24: 12 25-29: 31 >29: 32	[88]
Fischenich (2015)	USA	Knee	Meniscus (medial & lateral)	TKR	No	OA: 24	54	57.8 ± 4.6	31.9	[51]
Folkesson (2020)	Sweden	Knee	Meniscus (posterior)	OCS 4 medially;	Cadavers (w/o joint disease)	OA: 9 Control: 10	56 50	62.0 (50-75) 51.4 (18-77)	29.0 28.0	[52]

			horns of medial)	OCS 0-1 laterally						
Fuhrmann (2015)	Germany	Knee	Meniscus	TKR	No	OA: 9	67	69.6 (56-80)	NR	[53]
Ghosh (1975)	Australia	Knee	Meniscus	NR	No	OA: 5	NR	NR	NR	[54]
Grevenstein (2020)	Germany	Knee	Fat pad (infrapatellar)	TKR	Trauma (ACL rupture)	OA: 14 Control: 11	50 27	63.8 ± 17.6 33.7 ± 14.8	NR	[30]
Haut Donahue (2021)	USA	Knee	Meniscus (medial & lateral entheses)	TKR	No	OA: 7	NR	40-75	NR	[55]
Heinegård (1968)	Sweden	Knee	Capsule	NR	No	OA: 8	88	60-80	NR	[28]
Herbert (1973)	UK	Hip	Capsule	NR	Cadavers w/o joint disease	OA: 12 Control: 11*	NR NR	30-70 NR	NR NR	[29]
Hino (1995)	Japan	NR	Synovium	NR	No	OA: 4	NR	NR	NR	[122]
Hino (2020)	Japan	Knee	Meniscus (posterior root)	NR	No	OA: 7	57	75 (67-86)	NR	[56]
Ibrahim (2019)	Sweden	Shoulder	Tendon (biceps & subscapularis)	Total shoulder arthroplasty	Proximal humeral fracture	OA: 13 Control: 13	NR NR	Med 67 Med 70	NR NR	[132]
Ibrahim (2021)	Sweden	Hip	Tendon (Gluteus Medius)	Total hip arthroplasty	Femoral head fracture	OA: 29 Control: 25	66 76	70 73	NR NR	[133]
Ishizuka (2016)	Japan	Knee	Meniscus	TKR	No	OA: 30	57	71	NR	[57]
Itokazu (1998)	Japan	NR	Synovium	NR	Traumatic injury	OA: 22 Control: 16	41 25	59 21	NR NR	[123]
Jacquet (2018)	France	Knee	Meniscus	TKR	No	OA: 5	40	64	23.2	[58]
Jacquet (2019)	France	Knee	Meniscus (lateral)	Advanced medially, KL grade <2 laterally	No	OA: 24	50	64	NR	[59]

Johnson (2001)	USA	Knee	Meniscus (medial)	Advanced (joint replacement)	Cadavers	OA: 5 Control: 5	NR NR	NR NR	NR NR	[60]
Karjalainen (2021)	Finland	Knee	Meniscus (medial & lateral)	Outerbridge IV medially; 0/I medially	Cadavers	OA: 10 Control: 10	50 50	63 ± 7 51 ± 17	NR	[61]
Karube (1981)	Japan	Knee	Meniscus	NR	NR	OA: 3 Control: 17 <sup>#</sup>	NR	48-62 13-62 <sup>#</sup>	NR NR	[62]
Katsuragawa (2010)	Japan	Knee	Meniscus (ant. horn and body of medial and lateral)	End-stage	Cadavers w/o joint disease	OA: 40 Control: 22	NR NR	NR 84 (73-92)	NR NR	[63]
Kaufmann (2003)	Germany	Knee	Synovium	Knee replacement	No	OA: 21	76	71 (49-82)	NR	[98]
Kiraly (2017)	USA	Knee	Meniscus (posterior medial)	TKR	No	OA: 10	NR	NR	NR	[64]
Klareskog (1986)	Sweden	NR	Synovium	Arthroplasty	No	OA: 15	NR	NR	NR	[124]
Kodama (2018)	Japan	Knee	Meniscus (ant. & post. sections)	KL grade 4 (TKR)	No	OA: 26 menisci	84	76 ± 6.7 (68-84)	NR	[65]
Komro (2020)	USA	Knee	Ligament (ACL)	OCS mean 3.6 (range 3.2-4.0)	Cadaver (normal macroscopic ACL)	OA: 6 Control: 16	100 50	66 ± 9.6 75 ± 12.3	37.6 23.0	[36]
Konttinen (1999)	Finland	Hip	Synovium	NR	ACL tear (2), meniscal injury (3)	OA: 10 Control: 5	70 60	71 (41-84) 41 (22-53)	NR NR	[109]
Konttinen (2001)	Finland	Hip	Synovium	THA	No	OA: 10	60	70 (40-83)	NR	[110]
Kragstrup (2019)	USA	Knee	Synovium	KL grade 2-4	No	OA: 12	NR	NR	NR	[99]
Kriegsman (2004)	Germany	NR	Synovium	NR	No	OA: 3	NR	NR	NR	[125]
Kumagai (2012)	USA	Knee	Ligament (ACL & PCL)	Koshimoto's grade 3-5	No	OA: 28	82	77 (67-84)	NR	[37]

Kwok (2014)	USA	Knee	Meniscus	OARSI score 4	Healthy donors (OARSI 0-1)	OA: 3 Control: 3	NR NR	75 (61-90) 31 (20-41)	NR NR	[66]
Levy (2013)	USA	Knee	Ligament (ACL & PCL)	OCS score 0-4	Cadavers w/o joint degeneration	65 (111 OA & 9 control knees)	54	67 ± 19 (23-92)	24.8	[38]
Li (2000)	Finland	Hip	Synovium	Hip replacement	No	OA: 10	NR	NR	NR	[111]
Lopez-Franco (2016)	Spain	Knee	Meniscus (medial)	Knee replacement	No	OA: 31	74	72 ± 6.7 (60-84)	NR	[67]
Mapp (1985)	UK	Knee & hip	Synovium	NR	No	OA: 4	100	60.8 (46-69)	NR	[113]
Marczak (2017)	Poland	Knee	Ligament (PCL)	Ahlbäck grade 3-5	Cadavers w/o joint damage	OA: 50 Control: 10	80 70	71 (53-84) 72 (67-78)	NR NR	[39]
Martins (2018)	Brazil	Knee	Ligament (PCL)	Ahlbäck grade 1-5	No	OA: 85	81	70 (53-87)	NR	[40]
Masuda (1991)	Japan	Knee	Synovium, meniscus	NR	No	OA: 10	NR	76	NR	[68]
Mattiello-Sverzut (2013)	Brazil	Knee	Skeletal muscle (vastus lateralis)	KL grade 2.3 ± 1.2	No	OA: 6	33	62 ± 5	28.1	[89]
Mazzocca (2013)	USA	Shoulder	Tendon (long head of biceps)	NR	Cadavers w/o joint damage	OA: 9 Control: 9	22 56	59 ± 11.6 58 ± 14.7	NR NR	[134]
McDaniel (2017)	USA	Knee	Meniscus (medial & lateral)	Knee replacement	Cadavers w/o joint damage	OA: 14 Control: 14	50 64	62 ± 7.7 67 ± 10.6	34.6 NR	[69]
Meknas (2012)	Norway	Hip Tendon	Tendon (internal obturator)	NR	Femoral fracture	OA: 10 Control: 10	60 80	Med 60 (48-75) Med 83 (60-90)	NR NR	[135]
Melrose (2008)	Australia	Knee	Meniscus (medial & lateral)	Joint replacement	Cadavers w/o cartilage damage	OA: 17 Control: 6	11 NR	77.8 ± 5.4 (70-88) (60-75)	NR NR	[70]
Mine (2013)	Japan	Knee	Meniscus	TKR	No	OA: 12	NR	NR	NR	[71]

Mobargha (2014)	Sweden	Thumb	Ligament (volar anterior oblique & dorsoradial)	Eaton stage 2-3	No	OA: 11	91	67 (51-83)	NR	[46]
Monibi (2021)	USA	Knee	Meniscus (posterior medial)	Knee replacement	No	OA: 8	63	65 ± 5.5	NR	[72]
Musumeci (2014)	Italy	Knee	Meniscus (medial & lateral)	KL grade 2-3	ACL reconstruction	OA: 40 Control: 9	38 44	Med 68 (51-76) Med 60 (45-66)	NR NR	[73]
Nagata (2000)	Japan	Knee	Meniscus (medial)	KCS score: mean 52.6	No	OA: 11	73	79 (73-86)	NR	[74]
Nakahara (2013)	USA	Knee	Ligament (ACL)	KCS score 2-4	Normal cadaver, aged controls (cartilage score 1)	OA: 16 Cadaver: 13 Aged: 8	50 Unclear 63	80 ± 11.4 37 ± 11.0 77 ± 12.9	NR NR NR	[41]
Nakashima (1998)	Japan	Knee	Synovium	KCS score (2-4)	No	OA: 9	67	57 ± 8 (47-70)	NR	[100]
Nelissen (2001)	Netherlands	Knee	Ligament (PCL)	Ahlbäck grade 3-5	No	OA: 11	82	75 (60-85)	NR	[42]
Nikkari (1995)	Finland	Knee	Synovium	Knee replacement	No	OA: 6	NR	63	NR	[101]
Nishida (1995)	Japan	Knee	Synovium	Knee replacement	No	OA: 18	83	72 (62-86)	NR	[102]
Noehren (2018)	USA	Knee	Skeletal muscle (vastus lateralis)	KL grade 2-3	KL grade 0-1	OA: 24 Control: 15	42 67	60 ± 5.5 (52-73) 64 ± 6.9 (54-74)	28.4 26.9	[90]
Okamoto (2015)	Japan	TMJ	Synovium	NR	Cancer patient cadavers	OA: 5 Control: 3	60 67	60 (20-72) 64 (61-70)	NR NR	[120]
Park (2015)	South Korea	Knee	Meniscus (medial posterior root)	KL grade 3-4	Normal joint cadavers	OA: 99 Control: 3	NR 33	(50-85) 54 (47-61)	NR NR	[75]

Park (2021)	South Korea	Knee	Meniscus (medial & lateral)	Knee replacement	No	OA: 12	100	73 (65-82)	NR	[76]
Poduval (2010)	Finland	NR	Synovium	NR	Knee trauma	OA: 5 Control: 5	NR NR	NR NR	NR NR	[126]
Pollock (1990)	UK	Knee & hip	Synovium	NR	Trauma	OA: 7 Control: 4	71 50	69 (58-83) 38 (27-60)	NR NR	[114]
Pordzik (2020)	Germany	Knee	Meniscus (medial & lateral)	KL grade 4	NR	OA: 26 Control: 14	73 NR	Overall: 72 ± 6.7	NR	[77]
Rafael (2014)	Portugal	Knee	Synovium	Knee replacement	Normal joint cadaver	OA: NR Control: NR	NR NR	NR NR	NR NR	[103]
Rajgopal (2014)	India	Knee	Ligament (PCL)	KCS mean 42	No	OA: 62	74	67 ± 11 (49-91)	NR	[43]
Richardot (2009)	France	Knee	Synovium	Ahlbäck grade 3-5	No	OA: 4	100	(54-73)	NR	[104]
Rinaldi (1998)	Germany	Knee & hip	Synovium	NR	No	OA: 18	NR	NR	NR	[115]
Roller (2015)	USA	Knee	Meniscus (medial & lateral)	KL grade mean 3.94	Cadaver or amputation (KL 0)	OA: 23 Control: 5	NR NR	60 (36-81) 77 (64-87)	NR NR	[78]
Roller (2015)	USA	Knee	Meniscus	Mild to severe OA	Normal joint cadaver	OA: 6 Control: 3	50 NR	(44-69) (64-78)	NR NR	[79]
Saito (2002)	Japan	Knee	Synovium (medial & lateral)	Advanced disease	No	OA: 21	NR	64 (47-78)	NR	[105]
Santiago (2006)	Spain & France	NR	Synovium	NR	No	OA: 8	NR	NR	NR	[127]
Schneider (1994)	Germany	NR	Synovium	NR	Meniscal lesions	OA: 8 Control: 31	NR NR	NR NR	NR NR	[128]
Scott (1984)	UK	NR	Synovium	NR	Meniscal lesions	OA: 10	60	(37-72)	NR	[129]
Scott (1981)	UK	Hip & knee	Synovium	NR	No	OA: 8	63	61 (37-72)	NR	[116]
Serrao (2014)	Brazil	Knee	Skeletal muscle	KL grade 1-2	Healthy controls	OA: 18 Control: 17	NR NR	51 ± 6.3 52 ± 8.1	29.5 27.3	[91]



			(vastus lateralis)							
Sladojevic (2016)	Bosnia & Herzegovina	Knee	Meniscus (medial & lateral)	Advanced disease	No	OA: 35	86	69.3 (56-78)	30.8	[80]
Son (2013)	USA	Knee	Meniscus (medial & lateral)	TKR	No	OA: 14	57	65	NR	[81]
Sun (2010)	USA	Knee	Meniscus (posterior medial)	End-stage disease	No	OA: 8	6	57 (42-70)	NR	[82]
Sun (2012)	USA	Knee	Meniscus (medial)	End-stage disease	No	OA: 8	6	57 (42-70)	NR	[83]
Takahashi (1996)	Japan	Knee	Synovium	TKR	No	OA: 10	NR	58-79	NR	[106]
Takahashi (1998)	Japan	Knee	Meniscus (central & peripheral)	TKR	No	OA: 21	NR	69 (40-84)	NR	[84]
Turdean (2017)	Romania	Hip	Synovium	KL grade 3-4	No	OA: 57	44	64 (24-83)	NR	[112]
Van Linthoudt (1997)	USA	Hip & knee	Synovium	KL grade 2-4, mean 3.25	No	OA: 16	0	68 (54-76)	NR	[117]
Wang (2020)	UK	Knee	Meniscus (medial)	TKR	No	OA: 10	40	66 (46-87)	NR	[85]
Wang (2018)	China	Knee	Synovium	TKR	Lower limb amputation	OA: 31 Control: 5	Overall: 20	Overall: (48-69)	NR	[107]
Warnecke (2020)	Germany	Knee	Meniscus (lateral)	TKR	No	OA: 24	67	67 ± 9.0	29	[86]
Worrall (1991)	UK	NR	Synovium	TKR	Malignancy	OA: 8 Control: 5	63 NR	62 NR	NR NR	[130]
Worrall (1994)	UK	Knee & hip	Synovium	Replacement arthroplasty	(ankle, knee, elbow)	OA: 6 Control: 6	NR NR	NR NR	NR NR	[118]
Zhang (2012)	USA	Knee	Meniscus	NR	No	OA: 18	NR	(50-81)	NR	[87]
Zhu (2017)	China	Knee	Ligament (ACL)	TKR	No	OA: 20	NR	65 ± 5.6	NR	[44]

**Supplementary Table 2.** Study characteristics of animal studies. Joint of interest is the knee joint, unless otherwise specified. Age/time is reported in days (d), weeks (w), months (m), or years (y).

**Abbreviations:** ACL = anterior cruciate ligament, ACLT = anterior cruciate ligament transection, DJD = degenerative joint disease, DMM = destabilisation of the medial meniscus, LCL = lateral cruciate ligament, MCL = medial cruciate ligament, MIA = monoiodoacetate, NR = not reported, NZW = New Zealand White, OARSI = osteoarthritis research society international, PCL = posterior cruciate ligament.

\* = Lee *et al.* (2020): 11 animals (5 male and 4 female) were used across three groups: 2 OA groups and 1 control group.

Study (year)	Country	Species (strain)	OA model	Tissue (details)	Stage of disease / OA severity	Control population	No. of animals	Female (%)	Age at start of study (w/m/y)	Follow-up	Ref
Almasry (2015)	Saudi Arabia	Rat (Wistar albino)	Meniscectomy	Synovium	Early stage	Non-operated	OA: 15 Control: 15	0 0	Adult	6w	[154]
Anderson-Mackenzie (1999)	UK	Mouse (CBA, STR/ort)	STR/ort	Ligament (ACL & PCL)	NR	CBA mice	OA: 16 Control: NR	0 0	22/30/40/50w 22/30/40/50w	0w	[137]
Bansal (2020)	USA	Pig (Yucutan minipig)	DMM	Meniscus	NR	Sham surgery	OA: 13 Control: 11	0 0	6.8m 6.8m	1 & 3m	[152]
Barton (2021)	Canada	Sheep (Suffolk cross)	Partial ACL transection	Ligament (PCL), synovium	NR	Non-operated	OA: 11 Control: 6	100 100	3-5y 3-5y	20 & 40 w	[141]
Bedingfield (2021)	USA	Mouse (C57BL/6)	Mechanical loading	Meniscus, synovium	DJD score 5	Non-loaded	NR NR	NR NR	6m 6m	NR NR	[143]
Bryk (2021)	Poland	Rat (Wistar)	MIA	Synovium	NR	Non-injected	OA: 5-8 per time period Control: 1-2 per group	0 0	NR NR	2-28d	[155]
Castrogiovanni (2019)	Italy	Rat (Wistar)	ACLT	Synovium	OARSI score	NR	OA: 8 Control: 8	0 0	Adult Adult	14w	[156]

					3.25 ± 0.71							
Dai (2020)	China	Rat (Sprague- Dawley)	ACLT	Synovium (ant. & post.)	Early to late- stage OA	Sham surgery	OA: 36 Control: 36	0 0	12w 12w	4, 8 & 12w	[157]	
Endo (2018)	Japan	Rat (Wistar)	ACLT	Meniscus (medial & lateral)	OARSI score 1	Sham surgery	OA: 12 Control: 12	0 0	10w 10w	3w	[151]	
Funakoshi (2007)	Canada	Sheep (Suffolk cross)	ACL + MCL transection	Ligament (ACL & PCL)	NR	Non-operated	OA: 5 Control: 4	100 100	3y 3y	20w	[142]	
Gamal (2019)	Egypt	Rat (albino)	Cartilage defect	Synovium	NR	Non-operated	OA: 10 Control: 10	0 0	4-5m 4-5m	4 & 6w	[158]	
Hellio Le Graverand (2001)	France	Rabbit (NZW)	ACLT	Meniscus (medial & lateral)	NR	Non-operated	OA: 24 Control: 12	100 100	12m 12m	3 & 8w	[146]	
Hellio Le Graverand (2001)	Canada	Rabbit (NZW)	ACLT	Meniscus (medial)	NR	Non-operated	OA: 16 Control: 16	100 100	12m 12m	1, 2, 3, 4w	[147]	
Lapadula (1995)	Italy	Rabbit (Flanders giant)	Vitamin A injection	Synovium	Early stage	Untreated	OA: 12 Control: 4	0 0	8m 8m	3, 6, 9d	[164]	
Lee (2020)	USA	Mouse (BALB/cByJ)	DMM	Meniscus	NR	Sham surgery	OA: unclear* Ctrl: unclear*	* *	12w 12w	5w	[144]	
Levillain (2017)	France	Rabbit (NZW)	ACLT	Meniscus (medial)	Early stage	Non-operated	OA: 6 Control: 6	0 0	6m 6m	8w	[149]	
Levillain (2017)	France	Rabbit (NZW)	ACLT	Meniscus (medial)	Early stage	Non-operated	OA: 6 Control: 6	0 0	6m 6m	8w	[148]	
Li (2020)	China	Rat (Sprague- Dawley)	MIA	Synovium	NR	Sham surgery	OA: 6 Control: 6	0 0	8w 8w	8w	[159]	
Loeser (2013)	USA	Mouse (C57BL/6)	DMM	Meniscus, ligament, capsule, synovium	Early to end- stage	Sham surgery	OA: 36 Control: 36	0 0	12w 12w	2, 4, 8, 16w	[136]	

McErlain (2008)	Canada	Rat (Sprague-Dawley)	ACLT	Tendon (patellar)	NR	Sham surgery	OA: 15 Control: 3	0 0	3w 3w	1, 2, 3, 4, 5m	[166]
Miller (2014)	Canada	Rabbit (NZW)	ACLT	Ligament (MCL)	NR	Non-operated	OA: 6 Control: 6	100 100	1y 1y	6w	[140]
Muschter (2020)	Germany	Mouse (C57BL/6)	DMM	Meniscus	NR	Sham surgery	OA: 72 Control: 72	0 0	8-10w 8-10w	2, 4, 8, 12w	[145]
Ramos-Mucci (2020)	UK	Mouse (CBA, STR/ort)	STR/ort	Meniscus, ligaments (ACL, MCL, LCL)	OARSI grade 1-6	CBA mice	OA: 29 Control: 12	0 0	27, 37, 40w 26, 40w	N/A	[138]
Shi (2020)	China	Rabbit (NZW)	Adapted Videman method	Skeletal muscle (rec. fem & biceps fem)	NR	Non-operated	OA: 6 Control: 6	0 0	NR NR	10w	[153]
Walton (1977)	UK	Mouse (CBA, STR/ort)	STR/ort	Ligament	NR	CBA mice	OA: 351 Control: 348	36 28	4+m 4+m	NR NR	[139]
Wei (2021)	China	Rabbit (domestic)	Modified Hulth method	Synovium	OARSI score ~5 (4w) to ~11 (12w)	Sham surgery	OA: 15 Control: 5	NR NR	6m 6m	4, 12w	[165]
Zhang (2021)	China	Rabbit (Sprague- Dawley)	ACLT, DMM, MIA	Synovium	NR	'Normal'	Total: 80	0	NR	2, 4w	[161]
Zhang (2021)	China	Rabbit (Sprague- Dawley)	MIA	Synovium	NR	'Normal'	OA: 8 Control: 8	0 0	2m 2m	5w	[160]
Zhang (2019)	China	Rabbit (Sprague- Dawley)	MIA	Synovium	NR	Saline injection	OA: 6 Control: 6	100 100	3m 3m	4w	[163]
Zhang (2019)	China	Rabbit (Sprague- Dawley)	ACLT	Synovium	NR	'Normal'	OA: 8 Control: 8	0 0	3m 3m	4w	[162]

Zhao (2014)	China	Rabbit (Chinese)	Cartilage injury	Meniscus (interior)	NR	Sham surgery	OA: 12 Control: 12	100 100	20m 20m	1-6w	[150]
-------------	-------	---------------------	------------------	------------------------	----	--------------	-----------------------	------------	------------	------	-------

**Supplementary Table 3.** 2015 OHAT risk of bias analysis of all included studies. Bias in each category is rated according to the following 4-point scale: ++, definitely low risk of bias; +, probably low risk of bias; -, probably high risk of bias; --, definitely high risk of bias. Questions 1-6 only apply to certain study types. Of note, several studies on human OA did not recruit a healthy control group, but instead performed subgroup analysis of a single cohort. In these cases, confounding bias was assessed in question 11.

Abbreviations: A/EB = attrition/exclusion bias, CB = confounding bias, DB = detection bias, N/A = not applicable, OB = other bias, PB = performance bias, SB = selection bias, SRB = selective reporting bias.

Domains	SB			CB	PB		A/E B	DB		SRB	OB
	1	2	3	4	5	6	7	8	9	10	11
Abdul Sahib (2017)	N/A	N/A	-	-	N/A	N/A	+	-	--	-	++
Abraham (2014)	N/A	N/A	-	-	N/A	N/A	++	-	+	++	++
Akisue (2002)	N/A	N/A	-	-	N/A	N/A	++	++	+	++	++
Allain (2001)	N/A	N/A	N/A	N/A	N/A	N/A	++	-	-	++	-
Almasry (2015)	+	-	N/A	N/A	--	-	-	++	+	++	++
Anderson-Mackenzie (1999)	N/A	N/A	++	++	N/A	N/A	-	++	+	++	++
Bansal (2020)	-	-	N/A	N/A	+	-	-	++	++	++	++
Barton (2021)	-	-	N/A	N/A	-	-	-	+	++	+	++
Battistelli (2019)	N/A	N/A	-	-	N/A	N/A	-	++	-	--	--
Bedingfield (2021)	--	--	N/A	N/A	--	--	-	++	+	++	++
Belluzzi (2020)	N/A	N/A	++	++	N/A	N/A	-	-	+	++	++
Bryk (2021)	-	-	N/A	N/A	-	-	-	+	+	-	++
Cameron (1973)	N/A	N/A	-	-	N/A	N/A	+	-	-	-	-
Campbell (2015)	N/A	N/A	++	++	N/A	N/A	-	++	+	++	++
Castrogiovanni (2019)	-	-	N/A	N/A	-	-	-	++	++	++	++
Chang (2005)	N/A	N/A	-	-	N/A	N/A	-	-	+	++	++
Cheng (1996)	N/A	N/A	--	++	N/A	N/A	++	++	++	++	++
Christensen (2019)	N/A	N/A	--	--	N/A	N/A	+	+	-	++	++
Cillero-Pastor (2015)	N/A	N/A	-	-	N/A	N/A	+	-	+	++	++

Cutolo (1992)	N/A	N/A	-	-	N/A	N/A	+	++	-	-	-
Dai (2020)	+	-	N/A	N/A	++	-	+	++	+	++	++
Dessombz (2013)	N/A	N/A	N/A	N/A	N/A	N/A	--	++	+	+	++
DiCesare (1999)	N/A	N/A	-	-	N/A	N/A	+	-	+	+	++
DiFrancesco (1995)	N/A	N/A	+	+	N/A	N/A	++	-	-	-	+
Dijkgraaf (1997)	N/A	N/A	-	+	N/A	N/A	-	++	-	++	-
Doerschuk (1999)	N/A	N/A	-	-	N/A	N/A	-	++	-	+	++
Ea (2013)	N/A	N/A	-	-	N/A	N/A	+	++	++	++	-
Endo (2018)	+	-	N/A	N/A	+	-	-	++	-	+	++
Ene (2015)	N/A	N/A	-	-	N/A	N/A	+	+	-	--	++
Exposito Molinero (2016)	N/A	N/A	+	+	N/A	N/A	+	-	+	++	++
Fan (2012)	N/A	N/A	+	+	N/A	N/A	++	++	-	-	++
Fink (2007)	N/A	N/A	N/A	N/A	N/A	N/A	+	++	-	++	++
Fischenich (2015)	N/A	N/A	-	-	N/A	N/A	-	-	++	++	++
Folkesson (2020)	N/A	N/A	++	++	N/A	N/A	++	++	+	++	++
Fuhrmann (2015)	N/A	N/A	+	+	N/A	N/A	++	-	++	++	-
Funakoshi (2007)	-	-	N/A	N/A	-	-	+	++	+	++	++
Gamal (2019)	-	-	N/A	N/A	-	-	+	+	-	++	++
Ghosh (1975)	N/A	N/A	-	-	N/A	N/A	-	+	+	-	++
Grevenstein (2020)	N/A	N/A	-	-	N/A	N/A	++	-	-	++	++
Haut Donahue (2021)	N/A	N/A	++	++	N/A	N/A	+	-	+	++	++
Heinegård (1968)	N/A	N/A	-	-	N/A	N/A	++	+	+	++	--
LeGraverand (2001) (ref [146])	-	-	N/A	N/A	-	-	-	+	+	++	++
LeGraverand (2001) (ref [147])	-	-	N/A	N/A	-	-	-	+	-	++	++
Herbert (1973)	N/A	N/A	-	-	N/A	N/A	++	-	+	++	--
Hino (1995)	N/A	N/A	-	-	N/A	N/A	+	+	-	--	+
Hino (2020)	N/A	N/A	N/A	N/A	N/A	N/A	+	-	++	++	++
Ibrahim (2019)	N/A	N/A	++	++	N/A	N/A	+	+	+	++	++
Ibrahim (2021)	N/A	N/A	+	+	N/A	N/A	-	-	++	++	++
Ishizuka (2016)	N/A	N/A	--	--	N/A	N/A	--	++	-	++	-
Itokazu (1998)	N/A	N/A	-	-	N/A	N/A	++	-	--	++	--
Jacquet (2018)	N/A	N/A	N/A	N/A	N/A	N/A	+	++	++	++	++
Jacquet (2019)	N/A	N/A	N/A	N/A	N/A	N/A	+	++	+	++	++
Johnson (2001)	N/A	N/A	-	-	N/A	N/A	-	-	-	++	-
Karjalainen (2021)	N/A	N/A	--	++	N/A	N/A	++	++	+	++	++

Karube (1981)	N/A	N/A	-	-	N/A	N/A	++	-	+	++	-
Katsuragawa (2010)	N/A	N/A	+	+	N/A	N/A	-	++	-	++	++
Kaufmann (2003)	N/A	N/A	--	--	N/A	N/A	++	+	+	++	--
Kiraly (2017)	N/A	N/A	N/A	N/A	N/A	N/A	+	-	-	-	++
Klareskog (1986)	N/A	N/A	-	-	N/A	N/A	+	-	-	-	++
Kodama (2018)	N/A	N/A	N/A	N/A	N/A	N/A	--	++	-	++	++
Komro (2020)	N/A	N/A	--	--	N/A	N/A	+	++	+	++	+
Konttinen (1999)	N/A	N/A	-	-	N/A	N/A	++	-	-	++	-
Konttinen (2001)	N/A	N/A	+	+	N/A	N/A	-	-	+	++	++
Kragstrup (2019)	N/A	N/A	N/A	N/A	N/A	N/A	+	++	+	++	++
Kriegsmann (2004)	N/A	N/A	-	-	N/A	N/A	+	-	+	-	-
Kumagai (2012)	N/A	N/A	N/A	N/A	N/A	N/A	+	++	+	++	-
Kwok (2014)	N/A	N/A	-	-	N/A	N/A	++	++	-	++	-
Lapadula (1995)	+	-	N/A	N/A	-	-	+	-	-	-	--
Lee (2020)	-	-	N/A	N/A	-	-	-	+	-	-	++
Levillain (2017) (ref [149])	-	-	N/A	N/A	-	-	++	++	-	++	++
Levillain (2017) (ref [148])	+	-	N/A	N/A	-	-	-	++	-	++	++
Levy (2013)	N/A	N/A	N/A	N/A	N/A	N/A	-	+	++	++	-
Li (2000)	N/A	N/A	-	-	N/A	N/A	+	-	-	++	-
Li (2020)	+	-	N/A	N/A	+	-	-	+	+	++	++
Loeser (2013)	+	-	N/A	N/A	++	-	+	++	+	++	++
Lopez-Franco (2016)	N/A	N/A	-	-	N/A	N/A	++	+	++	++	++
Mapp (1985)	N/A	N/A	-	-	N/A	N/A	+	-	+	++	-
Marczak (2017)	N/A	N/A	++	++	N/A	N/A	++	++	-	++	++
Martins (2018)	N/A	N/A	-	-	N/A	N/A	++	++	+	++	++
Masuda (1991)	N/A	N/A	+	+	N/A	N/A	+	--	-	++	-
Mattiello-Svetzut (2013)	N/A	N/A	N/A	N/A	N/A	N/A	--	++	++	++	++
Mazzocca (2013)	N/A	N/A	+	+	N/A	N/A	--	+	++	++	++
McDaniel (2017)	N/A	N/A	++	++	N/A	N/A	+	++	-	++	++
McErlain (2008)	+	-	N/A	N/A	++	-	++	++	-	++	++
Meknas (2012)	N/A	N/A	-	-	N/A	N/A	+	-	+	++	++
Melrose (2008)	N/A	N/A	++	++	N/A	N/A	-	-	-	++	-
Miller (2014)	-	++	N/A	N/A	++	++	++	-	++	++	--
Mine (2013)	N/A	N/A	-	-	N/A	N/A	-	-	-	++	-
Mobargha (2014)	N/A	N/A	N/A	N/A	N/A	N/A	+	++	-	++	++



Monibi (2021)	N/A	N/A	-	-	N/A	N/A	-	-	++	+	++
Muschter (2020)	-	-	N/A	N/A	++	-	--	++	++	++	++
Musumeci (2014)	N/A	N/A	+	+	N/A	N/A	+	++	++	++	++
Nagata (2000)	N/A	N/A	-	-	N/A	N/A	++	++	-	++	-
Nakahara (2013)	N/A	N/A	+	+	N/A	N/A	--	++	-	--	+
Nakashima (1998)	N/A	N/A	N/A	N/A	N/A	N/A	++	++	-	++	++
Nelissen (2001)	N/A	N/A	-	-	N/A	N/A	++	++	-	++	-
Nikkari (1995)	N/A	N/A	-	-	N/A	N/A	++	-	-	++	-
Nishida (1995)	N/A	N/A	-	-	N/A	N/A	+	-	-	++	-
Noehren (2018)	N/A	N/A	+	+	N/A	N/A	-	++	++	++	++
Okamoto (2015)	N/A	N/A	+	+	N/A	N/A	++	++	-	++	-
Park (2015)	N/A	N/A	-	-	N/A	N/A	+	++	++	++	++
Park (2021)	N/A	N/A	N/A	N/A	N/A	N/A	++	-	+	++	++
Poduval (2010)	N/A	N/A	-	-	N/A	N/A	-	-	-	++	-
Pollock (1990)	N/A	N/A	-	-	N/A	N/A	+	-	-	++	-
Pordzik (2020)	N/A	N/A	+	+	N/A	N/A	+	++	+	++	++
Rafael (2014)	N/A	N/A	-	-	N/A	N/A	-	-	-	++	-
Rajgopal (2014)	N/A	N/A	N/A	N/A	N/A	N/A	++	+	+	++	++
Ramos-Mucci (2020)	N/A	N/A	++	++	N/A	N/A	-	++	-	-	-
Richardot (2009)	N/A	N/A	-	-	N/A	N/A	++	++	-	++	++
Rinaldi (1998)	N/A	N/A	-	-	N/A	N/A	-	++	+	++	-
Roller (2015) (ref [78])	N/A	N/A	++	++	N/A	N/A	+	++	+	++	++
Roller (2015) (ref [79])	N/A	N/A	-	-	N/A	N/A	--	++	++	+	-
Saito (2002)	N/A	N/A	N/A	N/A	N/A	N/A	-	++	+	++	++
Santiago (2006)											
Schneider (1994)	N/A	N/A	-	-	N/A	N/A	+	+	-	++	-
Scott (1981)	N/A	N/A	-	-	N/A	N/A	+	-	-	++	-
Scott (1984)	N/A	N/A	-	-	N/A	N/A	++	-	-	++	-
Serrão (2014)	N/A	N/A	++	++	N/A	N/A	++	++	+	++	-
Shi (2020)	+	-	N/A	N/A	+	-	-	+	+	+	++
Sladojevic (2016)	N/A	N/A	-	-	N/A	N/A	+	-	+	++	++
Son (2013)	N/A	N/A	N/A	N/A	N/A	N/A	+	-	+	++	++
Sun (2010)	N/A	N/A	-	-	N/A	N/A	+	-	++	++	++
Sun (2012)	N/A	N/A	-	-	N/A	N/A	++	-	++	++	++
Takahashi (1996)	N/A	N/A	-	-	N/A	N/A	+	++	+	++	++
Takahashi (1998)	N/A	N/A	--	++	N/A	N/A	+	+	+	-	++

Turdean (2017)	N/A	N/A	-	-	N/A	N/A	++	++	+	-	--
Van Linthoudt (1997)	N/A	N/A	N/A	N/A	N/A	N/A	++	++	+	++	++
Walton (1977)	N/A	N/A	-	-	N/A	N/A	-	+	-	-	+
Wang (2018)	N/A	N/A	-	-	N/A	N/A	+	++	+	++	++
Wang (2020)	N/A	N/A	N/A	N/A	N/A	N/A	++	++	++	++	++
Warnecke (2020)	N/A	N/A	-	-	N/A	N/A	-	-	+	++	++
Wei (2021)	+	-	N/A	N/A	-	-	+	++	++	++	++
Worrall (1991)	N/A	N/A	-	-	N/A	N/A	+	++	-	-	-
Worrall (1994)	N/A	N/A	-	-	N/A	N/A	+	++	-	++	++
Zhang (2012)	N/A	N/A	N/A	N/A	N/A	N/A	++	-	+	++	-
Zhang (2019) ref ([163])	+	-	N/A	N/A	++	-	+	+	-	-	++
Zhang (2019) ref ([162])	+	-	N/A	N/A	-	-	-	+	-	-	++
Zhang (2021) ref ([161])	++	-	N/A	N/A	-	-	+	+	+	+	++
Zhang (2021) ref ([160])	+	-	N/A	N/A	-	-	+	+	+	++	++
Zhao (2014)	+	-	N/A	N/A	++	-	+	++	-	++	-
Zhu (2012)	N/A	N/A	--	--	N/A	N/A	-	-	+	++	-

## Supplementary Information – search strategy

Database: Medline (Ovid MEDLINE® Epub Ahead of Print, In-Process & Other Non-Indexed Citations, Ovid MEDLINE® Daily and Ovid MEDLINE®) 1946 to present

Search Strategy:

- 
- 1 exp Proteoglycans/ (39384)
  - 2 exp Elasticity/ (50892)
  - 3 (elasticity or "elastic modulus" or topograph\* or anisotrop\*).ti,ab. (160630)
  - 4 exp Extracellular Matrix/ (47818)
  - 5 "extracellular matri\*".ti,ab. (106140)
  - 6 exp Extracellular Matrix Proteins/ (193763)
  - 7 (Aggrecan\* or "Cartilage Specific Proteoglycan Core Proteins" or COMP or "Thrombospondin 5" or TSP5 or collagen\* or pro-collagen\* or procollagen or tropocollagen\* or fibulin\* or "alpha-collagen" or elastin\* or thropoelastin\* or fibrillin\* or fibronectin\* or glycoprotein\* or laminin\* or "glycoprotein GP-2" or "latent TGF beta binding protein" or matrilin\* or MATN\* or "matrix protein\*" or netrin\* or netrin-1 or biglycan\* or decorin\* or hyalectin\* or neurocan\* or fibromodulin\* or lumican\* or tenacin\* or tenacin-c or cytotactin\* or hexabrachion\* or versican\* or "chondroitin sulfate proteoglycan core protein 2" or "chondroitin sulphate proteoglycan core protein 2" or vitronectin\* or pyridinoline\* or hydroxylysylpyridinoline\*).ti,ab. (448428)
  - 8 microfibril\*.ti,ab. (4325)
  - 9 exp Glycosaminoglycans/ (121397)
  - 10 (glycosaminoglycan\* or mucopolysaccharide\* or proteoglycan\* or chondroitin or translagen or blutal or heparin or "heparinic acid" or heparitin or heparan or "hyaluronic acid" or hyaluron\*n or hyaluronate or keratan or keratosulphate or keratosulfate).ti,ab. (160866)
  - 11 Calcinosis/ (38846)
  - 12 (calcinosis or calcinoses or calcification\* or microcalcification\* or microcalcinosis or microcalcinoses or hydroxyapatite or hydroxylapatite).ti,ab. (93466)
  - 13 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 (1009050)
  - 14 exp Intervertebral Disc/ (15222)
  - 15 ("intervertebral dis\*" or "annulus fibrosus" or "anulus fibrosis" or "nucleus pulposus").ti,ab. (18128)
  - 16 exp Ligaments, Articular/ (32725)
  - 17 ligament\*.ti,ab. (85003)
  - 18 exp Muscle, Skeletal/ (283110)
  - 19 muscle\*.ti,ab. (744181)
  - 20 exp Tendons/ (44653)
  - 21 tendon\*.ti,ab. (70548)
  - 22 Menisci, Tibial/ (7362)
  - 23 (menisc\* or "semilunar cartilage\*").ti,ab. (18889)

- 24 exp Joint Capsule/ (29528)
- 25 ("joint capsule\*" or "articular capsule\*" or "capsula articularis" or "synovial capsule\*" or "synovial fold\*" or "synovial plica\*" or "hip capsule\*" or "knee capsule\*" or "shoulder capsule\*").ti,ab. (3859)
- 26 Bursa, Synovial/ (1124)
- 27 ("synovial bursa\*" or synovium or "synovial membrane\*").ti,ab. (11261)
- 28 exp Adipose Tissue/ (103687)
- 29 ("adipose tissue\*" or "body fat\*" or "body pad\*" or "fat\* tissue\*" or "fat pad\*").ti,ab. (123620)
- 30 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26 or 27 or 28 or 29 (1173134)
- 31 exp Osteoarthritis/ (68777)
- 32 (osteoarthr\* or "degenerative arthri\*" or arthroses or arthrosis).ti,ab. (85531)
- 33 31 or 32 (105393)
- 34 13 and 30 and 33 (4268)
- 35 34 (4268)
- 36 limit 35 to yr="2020 - 2021" (490)

**Database: Embase 1974 to present**

Search Strategy:

- 
- 1 proteoglycan/ (24376)
  - 2 exp elasticity/ (69514)
  - 3 (elasticity or "elastic modulus" or topograph\* or anisotrop\*).ti,ab. (166957)
  - 4 exp extracellular matrix/ (153794)
  - 5 "extracellular matri\*".ti,ab. (134542)
  - 6 exp scleroprotein/ (346147)
  - 7 (Aggrecan\* or "Cartilage Specific Proteoglycan Core Proteins" or COMP or "Thrombospondin 5" or TSP5 or collagen\* or pro-collagen\* or procollagen or tropocollagen\* or fibulin\* or "alpha-collagen" or elastin\* or thropoelastin\* or fibrillin\* or fibronectin\* or glycoprotein\* or laminin\* or "glycoprotein GP-2" or "latent TGF beta binding protein" or matrilin\* or MATN\* or "matrix protein\*" or netrin\* or netrin-1 or biglycan\* or decorin\* or hyalectin\* or neurocan\* or fibromodulin\* or lumican\* or tenacin\* or tenacin-c or cytotactin\* or hexabrachion\* or versican\* or "chondroitin sulfate proteoglycan core protein 2" or "chondroitin sulphate proteoglycan core protein 2" or vitronectin\* or pyridinoline\* or hydroxylsypylpyridinoline\*).ti,ab. (555848)
  - 8 microfibril\*.ti,ab. (4450)
  - 9 exp glycosaminoglycan/ (250102)
  - 10 (glycosaminoglycan\* or mucopolysaccharide\* or proteoglycan\* or chondroitin or translagen or blutal or heparin or "heparinic acid" or heparitin or heparan or "hyaluronic acid" or hyaluron\*n or hyaluronate or keratan or keratosulphate or keratosulfate).ti,ab. (203041)
  - 11 exp calcinosis/ (16203)

- 12 (calcinosis or calcinosis or calcification\* or microcalcification\* or microcalcinosis or microcalcinosis or hydroxyapatite or hydroxylapatite).ti,ab. (118865)
- 13 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 (1369541)
- 14 exp intervertebral disk/ (16400)
- 15 ("intervertebral dis\*" or "annulus fibrosus" or "anulus fibrosis" or "nucleus pulposus").ti,ab. (21310)
- 16 exp joint ligament/ (28620)
- 17 ligament\*.ti,ab. (103603)
- 18 exp skeletal muscle/ (367283)
- 19 muscle\*.ti,ab. (919762)
- 20 exp tendon/ (41624)
- 21 tendon\*.ti,ab. (82988)
- 22 knee meniscus/ (10357)
- 23 (menisc\* or "semilunar cartilage\*").ti,ab. (22980)
- 24 joint capsule/ (3803)
- 25 ("joint capsule\*" or "articular capsule\*" or "capsula articularis" or "synovial capsule\*" or "synovial fold\*" or "synovial plica\*" or "hip capsule\*" or "knee capsule\*" or "shoulder capsule\*").ti,ab. (4819)
- 26 synovial bursa/ (2550)
- 27 ("synovial bursa\*" or synovium or "synovial membrane\*").ti,ab. (15675)
- 28 exp adipose tissue/ (176340)
- 29 ("adipose tissue\*" or "body fat\*" or "body pad\*" or "fat\* tissue\*" or "fat pad\*").ti,ab. (166084)
- 30 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26 or 27 or 28 or 29 (1411380)
- 31 exp osteoporosis/ (138070)
- 32 (osteoarthr\* or "degenerative arthri\*" or arthroses or arthrosis).ti,ab. (119642)
- 33 31 or 32 (253893)
- 34 13 and 30 and 33 (6543)
- 35 34 (6543)
- 36 limit 35 to yr="2020 - 2021" (909)

## Scopus

(( TITLE-ABS-KEY ( elasticity OR "elastic modulus" OR topograph\* OR anisotrop\* OR "extracellular matri\*" OR aggrecan\* OR "Cartilage Specific Proteoglycan Core Proteins" OR comp OR "Thrombospondin 5" OR tsp5 OR collagen\* OR pro-collagen\* OR procollagen OR tropocollagen\* OR fibulin\* OR "alpha-collagen" OR elastin\* OR thropoelastin\* OR fibrillin\* OR fibronectin\* OR glycoprotein\* OR laminin\* OR "glycoprotein GP-2" OR "latent TGF beta binding protein" OR matrilin\* OR matn\* OR "matrix protein\*" OR netrin\* OR netrin-1 OR biglycan\* OR decorin\* OR hyalectin\* OR neurocan\* OR fibromodulin\* OR lumican\* OR tenacin\* OR tenacin-

c OR cytotactin\* OR hexabrachion\* OR versican\* OR "chondroitin sulfate proteoglycan core protein 2" OR "chondroitin sulphate proteoglycan core protein 2" OR vitronectin\* OR pyridinoline\* OR hydroxylysylpyridinoline\* ) OR TITLE-ABS-KEY ( microfibril\* OR glycosaminoglycan\* OR mucopolysaccharide\* OR proteoglycan\* OR chondroitin OR translagen OR blutal OR heparin OR "heparinic acid" OR heparitin OR heparan OR "hyaluronic acid" OR hyaluron\*n OR hyaluronate OR keratan OR keratosulphate OR keratosulfate OR calcinosis OR calcinoses OR calcification\* OR microcalcification\* OR microcalcinosis OR microcalcinoses OR hydroxyapatite OR hydroxylapatite ) ) AND ( ( TITLE-ABS-KEY ( ( "intervertebral dis\*" OR "annulus fibrosus" OR "anulus fibrosis" OR "nucleus pulposus" ) ) OR TITLE-ABS-KEY ( ligament\* OR muscle\* OR tendon\* OR menisc\* OR "semilunar cartilage\*" OR ( "joint capsule\*" OR "articular capsule\*" OR "capsula articularis" OR "synovial capsule\*" OR "synovial fold\*" OR "synovial plica\*" OR "hip capsule\*" OR "knee capsule\*" OR "shoulder capsule\*" ) OR ( "synovial bursa\*" OR synovium OR "synovial membrane\*" ) OR ( "adipose tissue\*" OR "body fat\*" OR "body pad\*" OR "fat tissue\*" OR "fat pad\*" ) ) ) ) AND ( TITLE-ABS-KEY ( osteoarthr\* OR "degenerative arthri\*" OR arthroses OR arthrosis ) ) AND ( LIMIT-TO ( PUBYEAR , 2022 ) OR LIMIT-TO ( PUBYEAR , 2021 ) OR LIMIT-TO ( PUBYEAR , 2020 ) )